Product Information
TRELEGY ELLIPTA 200-62.5-25 is a brand product labeled by GlaxoSmithKline LLC, priced at $11.1531 per EA under NDC 00173089310. Its NADAC has been published 292 times since Jan 20, 2021.
FDA first approved this application on Sep 18, 2017.
TRELEGY ELLIPTA 200-62.5-25
fluticasone furoate, umeclidinium bromide and vilanterol trifenatateStrength
200; 62.5; 25 ug/1; ug/1; ug/1
Manufacturer
GlaxoSmithKline LLCNDC
00173089310
Classification
Brand
Dosage Form
POWDER
Route
RESPIRATORY (INHALATION)
Effective Date
8/19/2026
Active Ingredients
FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEApproval Type
New Drug (NDA)
FDA Application
NDA209482FDA Approved
9/18/2017
On Market Since
9/9/2020
Pharmacological Classes
Price Statistics
The NADAC for TRELEGY ELLIPTA 200-62.5-25 has been published 292 times since Jan 20, 2021, and over the history we have for it it has risen 16.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.1531 per EA |
|---|---|
| All-time high | $11.1626 (May 13, 2026) |
| All-time low | $9.5919 (Jan 20, 2021) |
| 52-week high | $11.1626 |
| 52-week low | $10.8332 |
| Median price | $10.2448 |
| Average price | $10.3361 |
| Largest weekly change | +3.0% (Feb 2, 2022) |
| Weeks tracked | 292 |
| Tracking since | Jan 20, 2021 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of TRELEGY ELLIPTA 200-62.5-25?
The current National Average Drug Acquisition Cost (NADAC) for TRELEGY ELLIPTA 200-62.5-25, manufactured by GlaxoSmithKline LLC, is $11.1531 per EA (NDC 00173089310), effective Aug 19, 2026.
How has the price of TRELEGY ELLIPTA 200-62.5-25 changed over time?
Over the history we have for it, the NADAC for TRELEGY ELLIPTA 200-62.5-25 has risen 16.3%. It has been tracked across 292 weekly CMS publications since Jan 20, 2021.
What are the highest and lowest recorded NADAC prices for TRELEGY ELLIPTA 200-62.5-25?
Since Jan 20, 2021, the NADAC for TRELEGY ELLIPTA 200-62.5-25 has ranged from a low of $9.5919 (Jan 20, 2021) to a high of $11.1626 (May 13, 2026), with a median of $10.2448 per EA.
Are there cheaper alternatives to TRELEGY ELLIPTA 200-62.5-25?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as TRELEGY ELLIPTA 200-62.5-25 in a comparable dosage form, but none are currently priced below it.
Who manufactures TRELEGY ELLIPTA 200-62.5-25?
TRELEGY ELLIPTA 200-62.5-25 (NDC 00173089310) is labeled by GlaxoSmithKline LLC, and CMS classifies it as a brand product.